Hunan Province’s Medical Security Administration has released a notice detailing the handling of complaints regarding the drug listing applications for new drugs, reference formulations, and approved drugs in May 2025. The announcement, published on May 27, 2025, reflects the province’s commitment to transparency and accountability in its pharmaceutical procurement process.
During the public display period of the application results, a total of five complaints were received. The handling opinions have been integrated into Hunan’s Medical Security Information Platform’s tender and procurement management system. Companies involved are required to check the complaint module for specific outcomes.
For products with reconfirmed price limits, companies must confirm the prices in the price linkage management module by 5:00 PM on May 30, 2025. Failure to do so will result in the products being included in the next round of reapplication. This strict timeline underscores the importance of prompt action by pharmaceutical companies to ensure compliance and avoid delays in market access.
Strategic Implications for Pharmaceutical Companies
The notice serves as a clear directive for pharmaceutical companies operating in Hunan Province. It highlights the need for vigilance during the application and public display periods, as well as the importance of timely response to any complaints or adjustments required by the regulatory authority.
For companies with products undergoing price reconfirmation, the deadline is a critical factor. Missing the deadline could lead to significant delays, potentially affecting market entry and revenue generation. Therefore, companies must prioritize efficient communication channels and ensure that their internal processes are aligned with the regulatory requirements.
Broader Context and Future Outlook
This policy reflects a broader trend in China’s pharmaceutical sector, where regulatory authorities are increasingly focusing on transparency and accountability in drug procurement. Hunan Province’s initiative is part of a nationwide effort to streamline the drug listing process and enhance the efficiency of the healthcare supply chain.
Looking ahead, pharmaceutical companies should expect continued scrutiny of their applications and a need for robust compliance mechanisms. The use of digital platforms for complaint handling and price confirmation also highlights the importance of technological proficiency in navigating the regulatory environment.-China Health Reform Pulse
Policy Source: http://ybj.hunan.gov.cn/ybj/first113541/firstF/f3113607/202505/t20250527_33684054.html